Online citations, reference lists, and bibliographies.

Phage Display-Derived Peptide-Based Dual-Modality Imaging Probe For Bladder Cancer Diagnosis And Resection Postinstillation: A Preclinical Study

Li Peng, Wenting Shang, Pengyu Guo, Kunshan He, Hong-zhi Wang, Ziyu Han, Hongmei Jiang, Jie Tian, Kun Wang, Wanhai Xu
Published 2018 · Biology, Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Bladder cancer is a common human malignancy. Conventional ultrasound and white-light cystoscopy are often used for bladder cancer diagnosis and resection, but insufficient specificity results in a high bladder cancer recurrence rate. New strategies for the diagnosis and resection of bladder cancer are needed. In this study, we developed a highly specific peptide-based probe for bladder cancer photoacoustic imaging (PAI) diagnosis and near-infrared (NIR)-imaging-guided resection after instillation. A bladder cancer–specific peptide (PLSWT7) was selected by in vivo phage-display technology and labeled with IRDye800CW to synthesize a bladder cancer–specific dual-modality imaging (DMI) probe (PLSWT7-DMI). The feasibility of PLSWT7-DMI–based dual-modality PAI-NIR imaging was assessed in vitro, in mouse models, and ex vivo human bladders. An air-pouch bladder cancer (APBC) model suitable for probe instillation was established to evaluate the probe-based bladder cancer PAI diagnosis and NIR-imaging–guided resection. Human bladders were used to assess whether the PLSWT7-DMI–based DMI strategy is a translatable approach for bladder cancer detection and resection. The probe exhibited excellent selectivity and specificity both in vitro and in vivo. Postinstillation of the probe, tumors <3 mm were detectable by PAI, and NIR-imaging–guided tumor resection decreased the bladder cancer recurrence rate by 90% and increased the survival in the mouse model. Additionally, ex vivo NIR imaging of human bladders indicated that PLSWT7-DMI–based imaging would potentially allow precise resection of bladder cancer in clinical settings. This PLSWT7-DMI–based DMI strategy was a translatable approach for bladder cancer diagnosis and resection and could potentially lower the bladder cancer recurrence rate. Mol Cancer Ther; 17(10); 2100–11. ©2018 AACR.
This paper references
10.1152/physrev.00049.2010
A molecular imaging primer: modalities, imaging agents, and applications.
Michelle L. James (2012)
10.1126/science.1216210
Photoacoustic Tomography: In Vivo Imaging from Organelles to Organs
Lihong V. Wang (2012)
10.1007/s11307-017-1106-6
Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide
Benjamin M. Larimer (2017)
10.1016/j.eururo.2013.06.003
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Marko Babjuk (2013)
10.1016/j.copbio.2006.10.002
Therapeutic peptides: technological advances driving peptides into development.
Aaron K. Sato (2006)
10.1002/cncr.25523
Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy : A multicenter randomized, double-blind, placebo-controlled trial.
Arnulf Stenzl (2011)
Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer.
Benjamin M. Larimer (2014)
10.1023/A:1020863921840
Exploring privileged structures: the combinatorial synthesis of cyclic peptides
Douglas A. Horton (2002)
10.3322/caac.21350
Current concepts in the diagnosis and pathobiology of intraepithelial neoplasia: A review by organ system.
Lysandra Voltaggio (2016)
10.1158/1078-0432.CCR-15-2715
Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study
Maria Frantzi (2016)
10.1002/cncr.28905
Novel endoscopic diagnosis for bladder cancer.
Seth P. Lerner (2015)
10.1158/1541-7786.MCR-06-0069
Targeting Bladder Tumor Cells In vivo and in the Urine with a Peptide Identified by Phage Display
Seung Min Lee (2007)
10.1038/sj.cgt.7700261
An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies
Takafumi Watanabe (2000)
10.1007/s11307-011-0479-1
Evaluation of 64Cu Labeled GX1: A Phage Display Peptide Probe for PET Imaging of Tumor Vasculature
Kai Chen (2011)
10.1016/j.juro.2012.03.127
New optical imaging technologies for bladder cancer: considerations and perspectives.
Jen‐Jane Liu (2012)
10.1021/acs.nanolett.6b00108
Super-Resolution Ultrasound Imaging in Vivo with Transient Laser-Activated Nanodroplets.
Geoffrey P. Luke (2016)
10.1038/srep10905
A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study
Zhangqun Ye (2015)
10.3322/caac.21338
Cancer statistics in China, 2015.
Wanqing Chen (2016)
10.1158/1078-0432.CCR-12-1188
Intraoperative Near-Infrared Imaging of Surgical Wounds after Tumor Resections Can Detect Residual Disease
Brian Madajewski (2012)
10.1016/j.eururo.2017.06.038
Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
Judith Bosschieter (2018)
10.1016/j.eururo.2014.06.037
Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
J. Alfred Witjes (2014)
10.1021/nl100890d
Ultrahigh sensitivity carbon nanotube agents for photoacoustic molecular imaging in living mice.
Adam de la Zerda (2010)
10.7150/thno.15878
Advances in Imaging Techniques and Genetically Encoded Probes for Photoacoustic Imaging
Chengbo Liu (2016)
10.2174/138161210790963788
Peptidic tumor targeting agents: the road from phage display peptide selections to clinical applications.
Kathlynn C. Brown (2010)
10.1126/scitranslmed.3009457
Endoscopic molecular imaging of human bladder cancer using a CD47 antibody
Ying Pan (2014)
10.1016/j.biomaterials.2016.07.026
Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer.
Tzu-yin Lin (2016)
10.1007/s00261-009-9540-9
Diagnosis of bladder cancer: contrast-enhanced ultrasound
Carlos Nicolau (2009)
A comparison of NBI andWLI cystoscopy in detecting non-muscle-invasive bladder cancer: a prospective, randomized and multi-center study
Z Ye (2018)
10.1016/j.urolonc.2010.06.011
Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach.
Hongyong Zhang (2012)
10.4103/0256-4947.51802
The accuracy of ultrasonography in the diagnosis of superficial bladder tumors in patients presenting with hematuria
Konstantinos Stamatiou (2009)
In vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging.
Mette Soendergaard (2014)
10.1016/j.eururo.2010.01.025
Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations.
Johannes Alfred Witjes (2010)
10.3892/or.2016.4829
A new non-muscle-invasive bladder tumor-homing peptide identified by phage display in vivo
Xiaofeng Yang (2016)
Cancer statistics in China
W Chen (2015)
Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: amulticenter randomized, double-blind, placebo-controlled trial
A Stenzl (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar